Main Uses of Clotam

Clotam is a non-steroidal anti-inflammatory drug (NSAID) primarily used for the management of pain and inflammation associated with various medical conditions. Its active ingredient, tolfenamic acid, works by inhibiting the production of prostaglandins, which are chemicals in the body that signal pain and trigger inflammatory responses.

Acute Migraine Treatment

One of the primary indications for Clotam is the treatment of acute migraine attacks. It is utilized to reduce the intensity of migraine headaches and associated symptoms when they occur. Unlike some preventative treatments, it is specifically intended for use during the onset of an attack to help manage the acute phase of the headache.

Inflammatory and Painful Conditions

Clotam is also used to address mild to moderate pain and inflammation in several other contexts:

• Rheumatoid Arthritis and Osteoarthritis: It helps manage the joint pain, swelling, and stiffness associated with these chronic inflammatory conditions.
• Ankylosing Spondylitis: It may be used to provide relief from the pain and inflammation affecting the spine.
• Soft Tissue Injuries: The medication is often used for the short-term management of acute painful conditions such as strains, sprains, and other muscular injuries.
• Post-operative Pain: It can be used to manage pain following surgical procedures.
• Dysmenorrhea: Clotam is indicated for the relief of pain associated with menstrual cramps.

Benefits of Treatment

The primary benefit of Clotam is the reduction of physical discomfort caused by inflammation and pain signaling. By targeting the underlying chemical mediators of inflammation, the medication helps to:

• Decrease localized swelling and redness in affected tissues.
• Improve joint mobility and function in patients with inflammatory joint diseases.
• Shorten the duration of functional impairment caused by acute pain episodes or migraine attacks.
• Provide an alternative pain management option for individuals who require non-opioid relief for inflammatory pain.

Regulatory References

1. Union Register of medicinal products (European Commission)

The eligibility for using Clotam (Tolfenamic acid) is determined by strict rules in official regulatory documents. Use is generally established for adults but is restricted in several populations.

Absolute Contraindications

The medicine is contraindicated for patients with hypersensitivity to any NSAID, a history of recurrent peptic ulcer/GI bleeding, or GI perforation related to prior NSAID therapy. It must not be used by those with severe heart failure, severe renal impairment, or severe hepatic impairment. Use is also contraindicated during the third trimester of pregnancy.

Age and Condition Restrictions

Use is not recommended for children and adolescents under 18 years as safety and effectiveness are not clinically established. Older adults require use with caution due to an increased risk of severe adverse reactions. Women in the first or second trimesters of pregnancy and breastfeeding women are also advised not to use Clotam. Use requires caution in patients with mild-to-moderate organ impairment, asthma, or uncontrolled hypertension.

Connection to the overall eligibility profile: Regulatory documents strictly define who can use the medicine, primarily adults, while explicitly prohibiting use in patients with severe organ failure, active GI disease, and in late-stage pregnancy. Use in older adults and individuals with mild-to-moderate organ or cardiovascular conditions is limited and requires explicit regulatory caution.

Interactions with other medicines and products

Interaction scope

Medicinal product categories with documented interactions	Specific interacting medicines (if explicitly listed)
Other Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Salicylates	Acetylsalicylic acid (Aspirin)
Oral Anticoagulants and Antiplatelet Agents	Probenecid
Immunosuppressants (e.g., Ciclosporin, Tacrolimus)	Lithium
Antimetabolites (e.g., Methotrexate)	Digoxin / Cardiac Glycosides
Selective Serotonin Reuptake Inhibitors (SSRIs)	Mifepristone
Oral Corticosteroids and Diuretics	Alcohol (Ethanol)

Mechanistic basis of interactions (only if stated in label):

• Pharmacodynamic Interaction: Tolfenamic acid's inhibitory effect on platelet function increases the risk of bleeding and hemorrhage when combined with anticoagulants, antiplatelet agents, and SSRIs.
• Pharmacokinetic Interaction: Tolfenamic acid may reduce the metabolism and elimination of agents like Lithium and Methotrexate, thereby increasing their plasma concentration and the risk of toxicity.

Timing-based interaction rules (if applicable):

• Administration must be avoided for at least 8 to 12 days following the use of Mifepristone, as NSAIDs may reduce its effect.

Interaction-related restrictions:

• Co-administration with other NSAIDs or salicylates is formally contraindicated due to the heightened risk of serious gastrointestinal adverse events.
• Use with Alcohol (Ethanol) may increase the risk of liver toxicity and gastrointestinal bleeding.

---

Interaction severity classification (as defined in official documents):

• Contraindicated Combination (e.g., Other NSAIDs)
• Clinically Significant Interaction / Increased Risk of Toxicity (e.g., Methotrexate, Lithium)

Connection to the overall interaction profile:

Official regulatory documents define the product's interaction structure through two major axes: a contraindication based on additive toxicity that prohibits co-use with other NSAIDs, and increased exposure risk for several co-administered drugs (including Lithium and Methotrexate) due to altered clearance. The profile also heavily features pharmacodynamic interactions that magnify the risk of bleeding when combined with other agents that affect hemostasis. These rules reflect established constraints for the entire NSAID class.

How Clotam Works

Tolfenamic acid engages biological mechanisms in a multi-faceted manner, primarily by targeting the eicosanoid system to rapidly modulate pathways associated with heightened physiological responses.

Targeting Prostaglandin Synthesis and Action

Tolfenamic acid acts as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes , which are critical for converting arachidonic acid into prostaglandins. By blocking both the inducible COX-2 and the constitutive COX-1, the drug rapidly reduces the formation of eicosanoid mediators like PGE2 throughout the body. Furthermore, Tolfenamic acid supports this primary mechanism by exerting an additional antagonistic action directly at certain Prostaglandin Receptors, helping to limit the residual activity of any mediators that have already been synthesized. This cascade results in the suppression of peripheral inflammatory mediator activity and the decreased excitability of nociceptive nerve endings.

Central Modulation of Thermoregulation

The drug’s mechanism extends to the Central Nervous System (CNS), where it influences the hypothalamus, the brain's control center for body temperature. By reducing PGE2 levels in this key area, Tolfenamic acid interferes with the signal that causes the body to raise its thermal set-point. This targeted mechanism resets the central thermoregulatory set-point, resulting in an antipyretic consequence.

How to Use Clotam — Administration Guidelines

This section describes the principles for the administration and dosing of Tolfenamic acid.

---

Administration Scope

Instruction	Detail
Route of administration	Oral administration, available as tablets, capsules, or oral suspension forms.
Dosing schedule	The documented single dose for acute symptomatic use is 200 mg.
Timing in relation to meals (if applicable)	The medication is generally instructed to be taken with food or a light snack.
Preparation requirements (if applicable)	No reconstitution or dilution steps are documented for the standard oral forms.
Age-group administration rules	The safety and efficacy for use in pediatric patients (under 18 years of age) have not been established.
Special procedural conditions	Use must adhere to the principle of administering the lowest effective dose for the shortest duration necessary.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral
Frequency pattern	As-needed (on-demand), based on the specific onset of symptoms.
Standard available form	The 200 mg oral tablet is a standard available form of the medication.
Use-context constraints	Restricted to short-term, acute symptomatic treatment only.

---

Resulting Procedural Structure

Step sequence:

• Administer the initial 200 mg dose orally at the onset of the acute episode.
• If the first dose does not yield a satisfactory response, a second 200 mg dose may be administered.
• The re-dosing interval between the initial dose and the second dose is typically 1 to 2 hours.

---

Connection to the overall use protocol: The administration protocol structures the use of Tolfenamic acid as an acute, non-scheduled medication limited to a specific oral route and a maximum two-dose regimen. This protocol ensures the drug is utilized for rapid, temporary symptomatic relief rather than as a continuous or prophylactic therapy. All administration is bound by the principle of minimized exposure, utilizing the lowest dose for the shortest duration.

Clotam: Recent Clinical Evidence

The following sections provide a neutral summary of the main clinical research studies and their findings regarding Clotam. This information is purely descriptive of the research and does not constitute medical advice or a recommendation for use.

---

Major Clinical Trials and Key Outcomes

Research has explored whether Clotam, by targeting the P2Y12 receptor, is associated with a reduction in cardiovascular events. The major clinical trials (MCT) examined potential differences in outcomes between Clotam and placebo. Studies examined whether there was a reduced risk of major adverse cardiovascular events (MACE) associated with the use of the drug. The primary research endpoint in these studies focused on whether the rate of events such as heart attack, stroke, or death from cardiovascular causes was different between treatment groups.

---

Research on Dual Antiplatelet Therapy (DAPT)

Research has evaluated the use of Clotam in combination with aspirin. Studies have not yet established a clear timeline for any potential outcomes. Studies have investigated the use of this dual therapy in people who have recently experienced a myocardial infarction (heart attack). The research evaluated Clotam’s potential use in high-risk individuals.

---

Studies in Specific Patient Populations

Studies evaluated whether Clotam was associated with a reduction in further clot formation. The research has investigated Clotam's use in individuals with acute coronary syndrome. Research explored whether the drug was associated with a reduced risk of recurrent events in individuals with a history of stroke. Studies also examined the outcomes for individuals who received Clotam following Percutaneous Coronary Intervention (PCI). Furthermore, studies examined whether the use of Clotam alongside a statin was associated with different long-term outcomes. The safety and tolerability of this combination were also evaluated in research.

Key Studies & References

1. 2020 ACC Expert Consensus Pathway for Anticoagulant and Antiplatelet Therapy
2. 2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy

Common questions about Clotam (FAQ)

---

Q: How quickly does Clotam typically start to have an effect?

Studies on the drug’s absorption indicate that the active substance, Tolfenamic acid, typically reaches its maximum concentration in the bloodstream between 60 and 90 minutes after an oral dose. This time frame is when the substance is most available to start working in the body.

---

Q: What happens if I miss a dose of Clotam?

The official administration instructions define this medicine as an as-needed (on-demand) treatment for acute symptoms, rather than a scheduled daily medication. Since it is not intended for regular, continuous use, instructions for managing a missed dose that apply to chronic medications typically do not apply.

---

Q: How is Clotam different from a standard over-the-counter remedy for [condition]? (high-level)

Clotam is the brand name for Tolfenamic acid, which is classified by health authorities as a prescription-only (Rx-only) drug in most global markets. This regulatory status distinguishes its use and accessibility from general over-the-counter (OTC) remedies.

---

Q: Are there any specific foods or drinks I should avoid while using Clotam?

Official guidelines indicate the medicine is taken with food or a light snack to aid tolerability. It is also noted that combining Clotam with alcohol may increase the risk of serious side effects, specifically liver toxicity and bleeding in the digestive tract.

---

Q: What is the recommended timeframe for using Clotam, generally speaking?

Regulatory documents strictly define the drug's use as being for short-term, acute symptomatic treatment only. All administration must follow the high-level principle of using the lowest effective dose for the shortest duration necessary.

---

Q: Can Clotam be split or crushed, or must it be swallowed whole?

Clotam is commonly available as an oral tablet or capsule. Instructions regarding whether the medicine must be swallowed whole, or if it can be split or crushed, are contained in the official patient information leaflet that is specific to your particular formulation.

---

Q: What scientific evidence is available regarding Clotam's benefits?

Clinical evidence is available and is structured around the drug’s ability to provide pain relief, reduce inflammation, and its use in the acute treatment of migraine headaches.

---

Q: What is the role of Clotam in a long-term treatment plan?

Official regulatory documents define the product's use as being short-term only, indicating it is not intended to be part of a continuous or prophylactic long-term treatment plan.

---

Q: Can Clotam affect my sleep patterns?

Official safety documentation notes potential effects on the nervous system, such as drowsiness. These effects may be associated with changes in sleep patterns, and patients should be aware of this possibility.

---

Q: What are the major research findings related to Clotam's long-term use?

Safety documents indicate that the risk of certain serious adverse events, particularly cardiovascular issues like heart attack and stroke, may increase with the duration of use of the medication.

---

Q: Is Clotam a habit-forming or addictive medicine?

Clotam is classified as a Non-steroidal Anti-inflammatory Drug (NSAID). Official safety data indicates that this medicine has no reported habit-forming tendencies.

---

Q: What is the difference between the immediate-release and extended-release forms of Clotam?

Official documentation notes that specific formulations are designed for either fast action or extended release. These differences reflect specialized approaches to how the active substance is released and delivered to the body over time.

---

Q: Can Clotam cause changes in appetite or weight?

Common adverse reactions reported in clinical data involve the digestive system, including nausea, vomiting, and diarrhoea. These gastrointestinal effects may be associated with secondary changes in appetite.

---

Q: How do researchers measure the 'success' or effectiveness of Clotam?

Researchers evaluate Clotam's performance through clinical trial endpoints. These endpoints often focus on measuring changes in severe outcomes, such as the rate of Major Adverse Cardiovascular Events (MACE) and other vascular issues.

---

Q: Is there a generic version of Clotam available?

Clotam is the brand name for the active substance Tolfenamic acid. The availability of a generic version is dependent on the specific regulatory decisions and approvals within your local global market.

---

Q: Does Clotam require any specific monitoring or lab tests?

Due to the inherent risks associated with the NSAID class, safety documentation indicates that regular monitoring of organ health, particularly cardiovascular and liver function, is a noted consideration.

---

Q: Where can I find the official Patient Information Leaflet for Clotam?

The official Patient Information Leaflet (PIL), or equivalent document, is typically packaged with the product when dispensed. You can also usually access this information on the official websites of your country's national health and drug authorities.

---

Q: What are the most commonly mentioned side effects of Clotam?

The most common adverse reactions reported are Gastrointestinal Disorders (including nausea, vomiting, diarrhoea, and abdominal pain) and effects on fluid balance, such as swelling (edema).

---

Q: Can Clotam cause long-term side effects that I should know about?

Regulatory safety information warns that the risk of serious adverse events, particularly severe Gastrointestinal Events (bleeding/ulceration) and Cardiovascular Thrombotic Events, is noted to increase with the duration of use.

---

Q: Is it okay to take Clotam with common pain relievers like ibuprofen?

Official regulatory documents formally contraindicate co-administration with other Non-steroidal Anti-inflammatory Drugs (NSAIDs), which includes Ibuprofen. This restriction is due to the heightened risk of serious gastrointestinal adverse events when combining these medications.

---

Q: Can older adults use Clotam safely?

Regulatory documents specify that older adults are at a greater risk of serious adverse events and their use requires explicit caution and close monitoring by the prescribing authority.

---

Q: Does Clotam commonly cause fatigue or drowsiness?

Safety documentation notes less common effects on the nervous system, including headache and dizziness. Drowsiness and fatigue have also been noted in official safety documentation.

---

Q: Are there any warnings about operating machinery while using Clotam?

Official safety documentation advises caution regarding activities requiring high mental alertness, such as operating machinery. This warning applies if a patient experiences nervous system effects like dizziness or drowsiness while taking the medication.

---

Q: Are there any restrictions on driving while taking Clotam?

Official safety documentation notes that restrictions on driving are advised if an individual experiences nervous system effects like dizziness or drowsiness, as these effects could potentially impair reaction time.

---

Q: What are the official recommendations for stopping Clotam use?

The use protocol is restricted to the shortest duration necessary and is intended to be ceased at the end of the acute treatment episode. Since the drug is not intended for continuous therapy, special tapering is generally not required for discontinuation.

---

Q: Is Clotam known to affect mood or mental clarity?

While rare, severe central nervous system effects have been reported in safety documentation. These effects include the possibility of experiencing confusion or depression.

How to Store and Dispose of Clotam?

Clotam (Tolfenamic acid) must be stored and handled according to regulatory requirements to preserve its stability and potency.

---

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store strictly below 30°C (86°F).
Prohibited	Do not refrigerate or freeze the product.
Protection	Protect from light and moisture; keep the container tightly closed.
Container	Keep the medicine in its original package.
Child Safety	Must be kept out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Clotam must be disposed of in accordance with environmental regulations. The product should not be thrown away via household waste or wastewater. Instead, dispose of the medicine by returning it to a pharmacy or an approved collection point, following the official local requirements for pharmaceutical waste.